
Effects of Nipradilol, a Nitric Oxide-Releasing β -Adrenoceptor Blocking Agent, on Phosphoenolpyruvate Carboxykinase Gene Transcription in a Rat Hepatoma Cell Line
Author(s) -
Kazuyo Yamauchi,
Koji Nakajima,
Sachiko Ikeo,
Yoshihiro Nishimura,
Mitsuhisa Komatsu,
Toru Aizawa,
Kiyoshi Hashizume
Publication year - 2001
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.87.83
Subject(s) - phosphoenolpyruvate carboxykinase , transcription (linguistics) , nitric oxide , chemistry , biology , microbiology and biotechnology , endocrinology , biochemistry , gene , philosophy , linguistics
Effects of nipradilol, a beta-adrenoceptor blocker with a nitroxy moiety, on phosphoenolpyruvate carboxykinase (PEPCK) gene transcription were examined using a rat hepatoma cell line, H4IIE cells. Dexamethasone was employed as an enhancer of PEPCK gene transcription. Nipradilol, but not timolol (a beta-blocker without a nitroxy moiety), attenuated PEPCK gene transcription both in the control and the dexamethasone-treated cells. The effects of nipradilol were eradicated by methylene blue (an inhibitor of cellular guanylate cyclase). Nipradilol is a unique beta-blocker that suppresses PEPCK gene transcription in hepatocytes likely through liberation of nitric oxide and resultant activation of guanylate cyclase.